Last reviewed · How we verify
Professor Anders Björkman — Portfolio Competitive Intelligence Brief
3 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Artesunate-amodiaquine given with single low dose primaquine | Artesunate-amodiaquine given with single low dose primaquine | marketed | ||||
| Coadministered Artesunate plus Amodiaquine | Coadministered Artesunate plus Amodiaquine | marketed | Antimalarial combination therapy | Plasmodium falciparum heme metabolism and protein synthesis | Infectious Disease | |
| Artesunate + Amodiaquine | Artesunate + Amodiaquine | marketed | Antimalarial combination | Plasmodium falciparum hemoglobin metabolism and DNA synthesis | Infectious Disease |
Therapeutic area mix
- Infectious Disease · 2
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Medicines for Malaria Venture · 2 shared drug classes
- Fundação de Medicina Tropical Dr. Heitor Vieira Dourado · 2 shared drug classes
- Centers for Disease Control and Prevention · 2 shared drug classes
- London School of Hygiene and Tropical Medicine · 2 shared drug classes
- University of Oxford · 2 shared drug classes
- Epicentre · 1 shared drug class
- Charite University, Berlin, Germany · 1 shared drug class
- Bernhard Nocht Institute for Tropical Medicine · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Professor Anders Björkman:
- Professor Anders Björkman pipeline updates — RSS
- Professor Anders Björkman pipeline updates — Atom
- Professor Anders Björkman pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Professor Anders Björkman — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/professor-anders-bj-rkman. Accessed 2026-05-16.